Shani Reich, MD
Ophthalmology · Pompano Beach, FLNPI 1144511288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 28.1% of the total. 2025 is the largest year on record at $1,068, 2.1 times the $506 reported in 2019.
Across 118 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sight Sciences, Inc.$379
- Alcon$325
- Aerie Pharmaceuticals, Inc.$202
- Mobius Therapeutics, LLC$200
- Amgen$191
- plus $1K from 18 others
Across 39 payments — averaging $12,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$252K
- Ocular Therapeutix, Inc.$225K
- Sumitomo Pharma America, Inc.$21K
What the payments were for
- Consulting fees$501%
- Speaking & faculty fees$2005%
- Food & beverage$3,54391%
- Education$672%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $1,091 |
| Sight Sciences, Inc. | 7 | $379 |
| Alcon | 9 | $325 |
| Aerie Pharmaceuticals, Inc. | 6 | $202 |
| Mobius Therapeutics, LLC | 1 | $200 |
| Amgen | 4 | $191 |
| Glaukos Corporation | 3 | $188 |
| Tarsus Pharmaceuticals, Inc. | 5 | $173 |
| Ocular Therapeutix, Inc. | 5 | $164 |
| Mallinckrodt Hospital Products Inc. | 6 | $156 |
| Sanofi | 1 | $141 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $127 |
| Bausch & Lomb Americas Inc. | 3 | $84 |
| Kala Pharmaceuticals, Inc. | 4 | $79 |
| Lensar, Inc. | 2 | $77 |
| Sun Pharmaceutical Industries Inc. | 2 | $65 |
| Novartis | 3 | $57 |
| Rxsight Inc | 2 | $41 |
| NEW World Medical,inc. | 2 | $38 |
| Biotissue Holdings Inc. | 2 | $27 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $17 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$273
- Mitosol$200
- SION SURGICAL INSTRUMENT$150
- iDose$149
- DUPIXENT$141
- Rhopressa$125
- Rocklatan$125
- TRYPTYR$125
- DURYSTA$125
- TEPEZZA$124
- XEN GLAUCOMA TREATMENT SYSTEM$114
How this compares
$3,877 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 320 | $117,979 |
| LumiganBimatoprost | 271 | $81,425 |
| RhopressaNetarsudil Mesylate | 205 | $74,800 |
| VyzultaLatanoprostene Bunod | 125 | $39,044 |
| CombiganBrimonidine Tartrate/Timolol | 113 | $33,470 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 98 | $21,456 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 278 | $12,577 |
| Alphagan PBrimonidine Tartrate | 36 | $11,204 |
| Brimonidine Tartrate | 382 | $7,924 |
| Prednisolone Acetate | 205 | $5,085 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 455 | $4,189 |
| Bimatoprost | 131 | $3,728 |
| ZioptanTafluprost/Pf | 13 | $3,555 |
| TafluprostTafluprost/Pf | 40 | $3,496 |
| Methazolamide | 33 | $3,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $202 | $192,779525 claims |
| AbbVieLumigan, Combigan, Alphagan P | $1,091 | $126,099420 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $84 | $39,044125 claims |
| AlconSimbrinza | $325 | $21,45698 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $24 | $1,61619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Pompano Beach
- Carl DanzigPompano Beach$484K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.